Taro Pharma (TARO) Reports Q3 EPS of $3.33
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/16/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Tweet
Share
E-mailGet Alerts TARO Hot Sheet
Join SI Premium – FREE
Taro Pharma (NYSE: TARO) reported Q3 EPS of $3.33, versus $2.59 reported last year. Revenue for the quarter came in at $237.7 million, versus $213.6 million reported last year.
For earnings history and earnings-related data on Taro Pharma (TARO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AIR Global sets first-ever dividend, $100M buyback amid business, cash strength
- Cohen & Steers (CNS) Misses Q3 EPS by 3c
- Alcoa (AA) Tops Q3 EPS by 28c, Misses on Revenue
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
